Metformin use is associated with a lower risk of uterine leiomyoma in female type 2 diabetes patients.
Taiwan
diabetes mellitus
metformin
uterine leiomyoma
Journal
Therapeutic advances in endocrinology and metabolism
ISSN: 2042-0188
Titre abrégé: Ther Adv Endocrinol Metab
Pays: United States
ID NLM: 101532143
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
04
2019
accepted:
24
11
2019
entrez:
4
1
2020
pubmed:
4
1
2020
medline:
4
1
2020
Statut:
epublish
Résumé
Whether metformin may reduce the risk of uterine leiomyoma in type 2 diabetes patients has not been investigated. This retrospective cohort study compared the risk of uterine leiomyoma in ever Female patients with new-onset type 2 diabetes during 1999-2005 were enrolled from the reimbursement database of Taiwan's National Health Insurance and followed up from 1 January 2006 until 31 December 2011. Analyses were conducted in a propensity score (PS) matched-pair cohort of 10,998 ever users and 10,998 never users of metformin. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using the PS. A total of 321 never users and 162 ever users developed uterine leiomyoma during follow up, with respective incidence of 704.65 and 329.82 per 100,000 person-years. The overall hazard ratio was 0.467 (95% confidence interval: 0.387-0.564). The hazard ratios for the first (<23.3 months), second (23.3-53.1 months), and third (>53.1 months) tertiles of cumulative duration were 0.881 (0.685-1.132), 0.485 (0.367-0.642), and 0.198 (0.134-0.291), respectively; and were 0.751 (0.576-0.980), 0.477 (0.360-0.632), and 0.277 (0.198-0.386), respectively, for the first (<655,000 mg), second 655,000-1,725,500 mg), and third (>1,725,500) tertiles of cumulative dose. Sensitivity analyses after excluding users of sulfonylurea, users of estrogen, users of insulin, users of incretin-based therapies during follow up, patients with irregular drug refills, patients who discontinued the use of metformin, patients who received metformin prescription less than four times, or redefining uterine leiomyoma by using 'diagnostic code' plus 'procedure codes' consistently supported a lower risk of uterine leiomyoma in ever users of metformin. Metformin use is associated with a lower risk of uterine leiomyoma.
Sections du résumé
BACKGROUND
BACKGROUND
Whether metformin may reduce the risk of uterine leiomyoma in type 2 diabetes patients has not been investigated. This retrospective cohort study compared the risk of uterine leiomyoma in ever
METHODS
METHODS
Female patients with new-onset type 2 diabetes during 1999-2005 were enrolled from the reimbursement database of Taiwan's National Health Insurance and followed up from 1 January 2006 until 31 December 2011. Analyses were conducted in a propensity score (PS) matched-pair cohort of 10,998 ever users and 10,998 never users of metformin. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using the PS.
RESULTS
RESULTS
A total of 321 never users and 162 ever users developed uterine leiomyoma during follow up, with respective incidence of 704.65 and 329.82 per 100,000 person-years. The overall hazard ratio was 0.467 (95% confidence interval: 0.387-0.564). The hazard ratios for the first (<23.3 months), second (23.3-53.1 months), and third (>53.1 months) tertiles of cumulative duration were 0.881 (0.685-1.132), 0.485 (0.367-0.642), and 0.198 (0.134-0.291), respectively; and were 0.751 (0.576-0.980), 0.477 (0.360-0.632), and 0.277 (0.198-0.386), respectively, for the first (<655,000 mg), second 655,000-1,725,500 mg), and third (>1,725,500) tertiles of cumulative dose. Sensitivity analyses after excluding users of sulfonylurea, users of estrogen, users of insulin, users of incretin-based therapies during follow up, patients with irregular drug refills, patients who discontinued the use of metformin, patients who received metformin prescription less than four times, or redefining uterine leiomyoma by using 'diagnostic code' plus 'procedure codes' consistently supported a lower risk of uterine leiomyoma in ever users of metformin.
CONCLUSION
CONCLUSIONS
Metformin use is associated with a lower risk of uterine leiomyoma.
Identifiants
pubmed: 31897287
doi: 10.1177/2042018819895159
pii: 10.1177_2042018819895159
pmc: PMC6920594
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2042018819895159Informations de copyright
© The Author(s), 2019.
Déclaration de conflit d'intérêts
Conflict of interest statement: The author declare that there is no conflict of interest.
Références
J Intern Med. 2017 Apr;281(4):319-336
pubmed: 27991713
Diabetologia. 2013 Sep;56(9):1898-906
pubmed: 23835523
Cell Tissue Res. 2016 May;364(2):415-27
pubmed: 26613601
Chin J Cancer. 2017 Jan 26;36(1):17
pubmed: 28126011
BMC Womens Health. 2017 Apr 11;17(1):28
pubmed: 28399866
Hum Reprod Update. 2018 Jan 1;24(1):59-85
pubmed: 29186429
J Obstet Gynaecol Can. 2015 Mar;37(3):277-285
pubmed: 26001875
BMJ. 2010 Mar 12;340:b5087
pubmed: 20228141
Int J Fertil Steril. 2016 Jan-Mar;9(4):424-35
pubmed: 26985330
Ginekol Pol. 2019;90(6):320-324
pubmed: 31276183
Epidemiology. 2009 Jul;20(4):604-10
pubmed: 19305350
Gynecol Obstet Invest. 2004;58(3):160-3
pubmed: 15249743
Diabetes Metab. 2017 Oct;43(5):438-445
pubmed: 28438547
Gynecol Oncol. 2015 Jul;138(1):147-53
pubmed: 25913129
CMAJ. 2006 Jan 31;174(3):319-23
pubmed: 16446472
Medicine (Baltimore). 2016 Nov;95(46):e5325
pubmed: 27861360
Gynecol Endocrinol. 2013 Jan;29(1):87-90
pubmed: 22835064
Eur J Endocrinol. 2012 Sep;167(3):409-16
pubmed: 22778198
BJOG. 2017 Sep;124(10):1501-1512
pubmed: 28296146
Oncotarget. 2017 Jun 20;8(25):41132-41142
pubmed: 28456789
Semin Reprod Med. 2017 Mar;35(2):181-189
pubmed: 28278535
Endocr Metab Immune Disord Drug Targets. 2015;15(3):196-205
pubmed: 25772174
Gynecol Obstet Invest. 2008;66(1):14-7
pubmed: 18230910
J Diabetes Investig. 2015 Nov;6(6):600-9
pubmed: 26543531
Reprod Sci. 2014 Sep;21(9):1187-95
pubmed: 25001017
Hum Reprod. 2015 Jan;30(1):61-70
pubmed: 25398968
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD002967
pubmed: 20091535
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Clin Sci (Lond). 2012 Mar;122(6):253-70
pubmed: 22117616
Yonsei Med J. 2019 Aug;60(8):791-795
pubmed: 31347335
Diabetes Care. 2012 Dec;35(12):2665-73
pubmed: 23173135
Stat Med. 2013 Jul 20;32(16):2837-49
pubmed: 23239115
Occup Environ Med. 2007 Aug;64(8):562-8
pubmed: 17053019
Mol Cell Endocrinol. 2015 Jan 5;399:1-8
pubmed: 25179820
Obstet Gynecol Surv. 2019 May;74(5):289-297
pubmed: 31098642